Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.

ABSTRACT:

Objectives

Despite the global impact of the Respiratory Syncytial Virus (RSV) infection in children, only one monoclonal antibody (Palivizumab) has been approved for clinical use. However, advances in the knowledge of RSV immunology may enable the development of safe and effective new vaccines and monoclonal antibodies in a few years. The purpose of this review is to summarize available data on approved and developing passive and active immunizations against RSV in childhood and pregnancy.

Data source

A non-systematic review of RSV immunoprophylaxis in childhood and pregnancy was carried out in PubMed, path.org and clinical trial registries, without language restrictions, up to September 2022.

Data synthesis

Three monoclonal antibodies and 17 active immunization candi

SUBMITTER: Scotta MC 

PROVIDER: S-EPMC10066449 | biostudies-literature | 2023 Mar-Apr

REPOSITORIES: biostudies-literature